title: Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease.
abstract: Treatment with omeprazole (OME), azithromycin (AZI) and amoxicillin (AMO) resulted in encouraging Helicobacter pylori cure rates in pilot and control studies. The aim of this study was to establish whether OME + AZI in combination with either AMO or ACA (amoxicillin plus clavulanic acid) are effective in curing H. pylori infection. A hundred patients with active duodenal ulcer and H. pylori infection were treated with OME (day 1-10: 2 x 40 mg/day, day 11-24: 40 mg/day, day 25-42: 20 mg/day) plus AZI 500 mg/day for the first 6 days. Patients were randomly assigned to either AMO 2 x 1000 mg/day (group A, n = 50) or ACA 2 x 1250 mg/day (group B, n = 50) during the first 10 days of treatment. H. pylori status was determined by urease test and histology before and 6 weeks after completion of therapy. Ninety-five patients completed the study. H. pylori infection was eradicated in 85.4% (41/48) patients from group A (intention-to-treat (ITT) analysis: 82%) versus 91.5% (43/47) patients from group B (ITT) analysis: 86%) (NS). All ulcer had healed after 42 days of omeprazole treatment. Side effects, usually minor, were recorded in 12.5% (group A) and 14.9% (group B) of patients (NS). Therapy had to be discontinued in two patients (one in group A and one group B) only. Ten-days treatment with OME and AZI (for the first 6 days) with AMO or ACA are simple and highly effective regimens to cure H. pylori infection in patients with duodenal ulcer disease.
authors.affiliation: Department of Medicine, Osijek University Hospital, Croatia.
authors.forename: A
authors.initials: A
authors.lastname: Vcev
authors.forename: A
authors.initials: A
authors.lastname: Vceva
authors.forename: B
authors.initials: B
authors.lastname: Takac
authors.forename: B
authors.initials: B
authors.lastname: Dmitrović
authors.forename: D
authors.initials: D
authors.lastname: Stimac
authors.forename: T
authors.initials: T
authors.lastname: Stimac
authors.forename: D
authors.initials: D
authors.lastname: Kovac
authors.forename: D
authors.initials: D
authors.lastname: Pezerović
authors.forename: A
authors.initials: A
authors.lastname: Blazanović
authors.forename: A
authors.initials: A
authors.lastname: Ivandić
authors.forename: I
authors.initials: I
authors.lastname: Karner
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D017963:Azithromycin / Q000008:administration & dosage; D019818:Clavulanic Acid / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D010406:Penicillins / Q000008:administration & dosage